Neonatal community-acquired pneumonia: pathogens and treatment.
OBJECTIVE
To analyse the bacterial pathogens and drug sensitivities for neonatal community-acquired pneumonia.


METHODS
Seven hundred sixty sputum samples from newborns with community-acquired pneumonia were cultured to determine microbial organisms present and their drug sensitivities.


RESULTS
Of the 760 specimens, 425 grew pathogens for a 55.9% positive rate. Among the 425 positive cultures, 278 grew gram-negative organisms (65.4%), 142 grew gram-positive organisms (33.3%), while 5 grew fungus (1.3%). The most common gram-negative organisms were Escherichia coli, Klebsiella pneumoniae and Hemophilus influenzae, while the most common gram-positive organisms were Staphylococcus aureus, Staphylococcus epidermidis and Staphylococcus haemolyticus. To the gram-negative organisms, the most sensitive drugs were meropenem, imipenem and amikacin, while to the gram-positive ones were vancomycin, teicoplanin and quinupristin/dalfopristin.


CONCLUSIONS
The most common causative bacteria were gram-negative organisms, which were highly sensitive to Meropenem, Imipenem and Amikacin, yet often treatable with more focused antibiotic coverage, which depended on the bacterium identified.
Wang
Hua
H
Department of Pediatrics, West China Second University Hospital, Sichuan University, Sichuan, China.
Tang
Jun
J
Xiong
Ying
Y
Li
Xihong
X
Gonzalez
Fernando
F
Mu
Dezhi
D
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002681:China; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology*; D024881:Drug Resistance, Bacterial; D005260:Female; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D007231:Infant, Newborn; D008297:Male; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology*; D012189:Retrospective Studies; D013183:Sputum / Q000382:microbiology; D013845:Thienamycins / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D013845:Thienamycins; D014640:Vancomycin; D015378:Imipenem; D000077731:Meropenem